The Circular RNA Landscape of Non-Small Cell Lung Cancer Cells

Autor: Andrea C. Becker, Nele Van Der Steen, Anne K Hitzler, Jeanette Seiler, Yanhong Lyu, Sven Diederichs

Publikováno v: Cancers
Volume 12
Issue 5
Cancers, Vol 12, Iss 1091, p 1091 (2020)

The class of circular RNA (circRNA) is characterized by head-to-tail bonds between exons formed by backsplicing. Here, we provide a resource of circRNA expression in a comprehensive panel of 60 lung cancer and non-transformed cell lines (FL3C dataset

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50adf8d8091b2373806c66e81724885c
https://pubmed.ncbi.nlm.nih.gov/32353949

Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC

Autor: Yves Mentens, Jose Ferri, Godefridus J. Peters, Elisa Giovannetti, Nele Van Der Steen, Paul Germonpré, M. Ramael, Patrick Pauwels, Leticia G. Leon, David R. Gandara, Christian Rolfo

Publikováno v: Van Der Steen, N, Mentens, Y, Ramael, M, Leon, L G, Germonpré, P, Ferri, J, Gandara, D R, Giovannetti, E, Peters, G J, Pauwels, P & Rolfo, C 2018, ' Double Trouble : A Case Series on Concomitant Genetic Aberrations in NSCLC ', Clinical Lung Cancer, vol. 19, no. 1, pp. 35-41 . https://doi.org/10.1016/j.cllc.2017.06.010
Clinical Lung Cancer, 19(1), 35-41. Elsevier
Clinical lung cancer

Several oncogenic drivers have been identified in non-small cell lung cancer. Targeted therapies for these aberrations have already been successfully developed and implemented in clinical practice. Owing to improved sensitivity in genetic testing, mo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::184d2225d523195834ff5aba158882ed
https://doi.org/10.1016/j.cllc.2017.06.010

Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line

Autor: Henk L. Dekker, Elisa Giovannetti, Marcello Tiseo, Patrick Pauwels, Filip Lardon, Christian Rolfo, Kaylee Keller, Rob Ruijtenbeek, Alessandro Leonetti, Niccola Funel, Godefridus J. Peters, Nele Van Der Steen

Publikováno v: Biochemical pharmacology
van der Steen, N, Leonetti, A, Keller, K, Dekker, H, Funel, N, Lardon, F, Ruijtenbeek, R, Tiseo, M, Rolfo, C, Pauwels, P, Peters, G J & Giovannetti, E 2019, ' Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line ', Biochemical Pharmacology, vol. 166, pp. 128-138 . https://doi.org/10.1016/j.bcp.2019.05.014
Biochemical Pharmacology, 166, 128-138. Elsevier Inc.

Introduction Lung squamous cell carcinomas (SCC) typically harbor a strong activation of epidermal growth factor receptor (EGFR) pathway. Since one of the most common resistance mechanisms against EGFR inhibition relies on the activation of cMET para

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::198c1da7976161631dcc7ca088486798
https://hdl.handle.net/10067/1611930151162165141

The Role of c-Met as a Biomarker and Player in Innate and Acquired Resistance in Non-Small-Cell Lung Cancer: Two New Mutations Warrant Further Studies

Autor: Marcello Tiseo, Godefridus J. Peters, Paul Germonpré, Christian Rolfo, Nele Van Der Steen, Christophe Hermans, Giulia Mazzaschi, Elisa Giovannetti, Karen Zwaenepoel, Daan P. Geerke, Patrick Pauwels, Paul Van Schil, Ken Op de Beeck, Filip Lardon, Rosa A. Luirink

Publikováno v: Molecules
Volume 24
Issue 24
Molecules: a journal of synthetic chemistry and natural product chemistry
Molecules, 24(24). Multidisciplinary Digital Publishing Institute
van der Steen, N, Zwaenepoel, K, Mazzaschi, G, A Luirink, R, P Geerke, D, op de Beeck, K, Hermans, C, Tiseo, M, van Schil, P, Lardon, F, Germonpré, P, Rolfo, C, Giovannetti, E, J Peters, G & Pauwels, P 2019, ' The Role of c-Met as a Biomarker and Player in Innate and Acquired Resistance in Non-Small-Cell Lung Cancer: Two New Mutations Warrant Further Studies ', Molecules, vol. 24, no. 24 . https://doi.org/10.3390/molecules24244443
Molecules, 24(24):4443. Multidisciplinary Digital Publishing Institute (MDPI)
Van Der Steen, N, Zwaenepoel, K, Mazzaschi, G, Luirink, R A, Geerke, D P, De Beeck, K O, Hermans, C, Tiseo, M, Van Schil, P, Lardon, F, Germonpré, P, Rolfo, C, Giovannetti, E, Peters, G J & Pauwels, P 2019, ' The role of c-met as a biomarker and player in innate and acquired resistance in non-small-cell lung cancer : Two new mutations warrant further studies ', Molecules, vol. 24, no. 24, 4443 . https://doi.org/10.3390/molecules24244443

The c-Met receptor is a therapeutically actionable target in non-small-cell lung cancer (NSCLC), with one approved drug and several agents in development. Most suitable biomarkers for patient selection include c-Met amplification and exon-14 skipping

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d41c017861e5a2eba24b3519c13c0ba8
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85076355617&origin=inward

List of Contributors

Autor: Andrea Cavazzoni, Francis Ka-Ming Chan, Alice P. Chen, William B. Coleman, Emmanuel K. Cudjoe, Deborah DeRyckere, Ingrid Garajova, David A. Gewirtz, Elisa Giovannetti, Douglas K. Graham, Jennifer R. Grandis, Garima Gupta, J. Silvio Gutkind, Cinta Hierro, Lanlin Hu, Daniel E. Johnson, Marwan Kwok, S. Lauren Kyte, Joseph W. Landry, David S. Lee, Katherine A. Minson, Kenta Moriwaki, Himani Nailwal, Rachel A. O'Keefe, Mary Quinn, Christian Rolfo, Tareq Saleh, Tatjana Stankovic, Ryan J. Summers, Josep Tabernero, Naoko Takebe, Nele Van Der Steen, Xiaolong Yang, Yulei Zhao, Richard T. Zhu, Fangdong Zou

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a11a099f8f8e19de756b2e5a51b3aba5
https://doi.org/10.1016/b978-0-12-813753-6.00017-2